Refinancing Group Facilities - Private Placement

RNS Number : 4273S

Dechra Pharmaceuticals PLC

14 July 2022

 

Thursday, 14 July 2022

Dechra^® Pharmaceuticals PLC

(Dechra, Company or the Group)

Refinancing of the Group Debt Facilities

Private Placement: Euro Senior Unsecured Notes

Dechra is pleased to announce the signing of a private placement of EUR50 million seven year and EUR 100 million ten year new senior unsecured notes.  The issue has similar covenants to the Group's existing facilities.  The weighted average coupon of the fixed rate notes will equate to 3.8%.

The issue was priced on 1 July 2022 and the agreement was signed on 14 July 2022.  The notes will be issued on 14 July 2022 subject to satisfaction of customary closing conditions.

The private placement is being undertaken now to achieve the Group's aim of ensuring diversified sources of funding and to extend the Group's debt maturity profile.  All proceeds from the placement will be used to repay existing debt on the Group's revolving Credit Facility.

Enquiries to:

Dechra Pharmaceuticals PLC

Ian Page, Chief Executive Officer

Paul Sandland, Chief Financial Officer

Office:  [phone]

e-mail: [e-mail]

TooleyStreet Communications Ltd

Fiona Tooley, Director

Mobile: [phone]

e-mail: [e-mail]

About Dechra

Dechra is a global veterinary pharmaceuticals and relates products business.  Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. For more information please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

STRGPUBPMUPPUUC